M. S. Suthar

This study shows that CD4+ and CD8+ T cells are necessary to prevent SARS-CoV-2 persistence in the nasal compartment but not in the lungs.

The paper uses scRNA-seq to analyze the antiviral response in human dendritic cells infected with ZIKV, identifying a network of host genes and proteins involved in antiviral defense.

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

This study examines how SARS-CoV-2 booster vaccines affect antibody profiles in myeloma patients, finding improved binding but not neutralization against variants.

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

This study shows that inhibiting CHK2 reduces ZIKV production and rescues developmental defects by enhancing STING-dependent antiviral responses.

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

This paper identifies and structurally analyzes an antibody that neutralizes SARS-CoV-2 BA.1 and BA.2 variants, revealing its unique epitope and mechanism of action.

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

This study develops a hybrid vaccine combining influenza VLPs with SARS-CoV-2 RBD and GM-CSF, showing protection against both viruses in mice.

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

This study shows that the timing of SARS-CoV-2 exposure, particularly during peak viral load, is the strongest determinant of transmission success in golden Syrian hamsters.

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

The paper profiles longitudinal immune responses in mild COVID-19 patients to identify recovery and persistence signatures.

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

This study shows that plasmacytoid dendritic cells recognize SARS-CoV-2, produce type I and III interferons, and reduce viral replication in infected airway epithelial cells.

This study creates a mouse-adapted SARS-CoV-2 strain that protects mice from lethal SARS-CoV challenge, demonstrating cross-strain immunity.

This study identifies a CCR2-dependent monocyte-derived cell mechanism that restricts SARS-CoV-2 infection and inflammation in the lungs of mice.

The paper compares antibody binding and neutralization against SARS-CoV-2 B.1 and B.1.351 variants in infected and vaccinated individuals, finding reduced titers but retained neutralization.

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

This study shows SARS-CoV-2 infects human airway epithelial cultures, induces pro-inflammatory cytokines, and is inhibited by type I and III IFNs.

The paper identifies STAT5 as a target of antagonism by WNV and ZIKV in human DCs, showing differential inhibition of Jak kinases compared to other flaviviruses.

This study shows West Nile virus infects human dendritic cells, activates antiviral responses, but suppresses T cell activation and cytokine production, impairing T cell immunity.

The paper uses WNV-inclusive scRNA-seq to show single-cell heterogeneity in IFN-I response and viral RNA abundance during WNV infection.